INTRODUCTION: The clinically established positron emission tomography (PET) tracers 6-[(18)F]-fluoro-l-DOPA ([(18)F]FDOPA), 6-[(18)F]-fluoro-l-m-tyrosine ([(18)F]FMT) and 2beta-carbomethoxy-3beta-(4-chlorophenyl)-8-(2-[(18)F]-fluoroethyl)-nortropane ([(18)F]FECNT) serve as markers of presynaptic integrity of dopaminergic nerve terminals in humans. This study describes our efforts to adopt the methodology of human Parkinson's disease (PD) PET studies to mice. METHODS: The PET imaging characteristics of [(18)F]FDOPA, [(18)F]FMT and [(18)F]FECNT were analyzed in healthy C57BL/6 mice using the dedicated small-animal PET tomograph quad-HIDAC. Furthermore, [(18)F]FECNT was tested in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. RESULTS: [(18)F]FDOPA and [(18)F]FMT failed to clearly visualize the mouse striatum, whereas PET experiments using [(18)F]FECNT proved that the employed methodology is capable of delineating the striatum in mice with exquisite resolution. Moreover, [(18)F]FECNT PET imaging of healthy and MPTP-lesioned mice demonstrated that the detection and quantification of striatal degeneration in lesioned mice can be accomplished. CONCLUSIONS: This study shows the feasibility of using [(18)F]FECNT PET to analyze noninvasively the striatal degeneration in the MPTP mouse model of PD. This methodology can be therefore considered as a viable complement to established in vivo microdialysis and postmortem techniques.
INTRODUCTION: The clinically established positron emission tomography (PET) tracers 6-[(18)F]-fluoro-l-DOPA ([(18)F]FDOPA), 6-[(18)F]-fluoro-l-m-tyrosine ([(18)F]FMT) and 2beta-carbomethoxy-3beta-(4-chlorophenyl)-8-(2-[(18)F]-fluoroethyl)-nortropane ([(18)F]FECNT) serve as markers of presynaptic integrity of dopaminergic nerve terminals in humans. This study describes our efforts to adopt the methodology of humanParkinson's disease (PD) PET studies to mice. METHODS: The PET imaging characteristics of [(18)F]FDOPA, [(18)F]FMT and [(18)F]FECNT were analyzed in healthy C57BL/6 mice using the dedicated small-animal PET tomograph quad-HIDAC. Furthermore, [(18)F]FECNT was tested in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. RESULTS: [(18)F]FDOPA and [(18)F]FMT failed to clearly visualize the mouse striatum, whereas PET experiments using [(18)F]FECNT proved that the employed methodology is capable of delineating the striatum in mice with exquisite resolution. Moreover, [(18)F]FECNT PET imaging of healthy and MPTP-lesioned mice demonstrated that the detection and quantification of striatal degeneration in lesioned mice can be accomplished. CONCLUSIONS: This study shows the feasibility of using [(18)F]FECNT PET to analyze noninvasively the striatal degeneration in the MPTPmouse model of PD. This methodology can be therefore considered as a viable complement to established in vivo microdialysis and postmortem techniques.
Authors: Zhude Tu; Jinda Fan; Shihong Li; Lynne A Jones; Jinquan Cui; Prashanth K Padakanti; Jinbin Xu; Dexing Zeng; Kooresh I Shoghi; Joel S Perlmutter; Robert H Mach Journal: Bioorg Med Chem Date: 2011-01-22 Impact factor: 3.641
Authors: Gunasingh Masilamoni; John Votaw; Leonard Howell; Rosa M Villalba; Mark Goodman; Ronald J Voll; Jeffrey Stehouwer; Thomas Wichmann; Yoland Smith Journal: Exp Neurol Date: 2010-09-09 Impact factor: 5.330
Authors: Ronald L Klein; Robert D Dayton; Tracee L Terry; Chris Vascoe; John J Sunderland; Kerrie H Tainter Journal: Brain Res Date: 2009-02-10 Impact factor: 3.252
Authors: James S Toomey; Shilpa Bhatia; La'Wanda T Moon; Elysse A Orchard; Kerrie H Tainter; Stephen J Lokitz; Tracee Terry; J Michael Mathis; Andrew D Penman Journal: PLoS One Date: 2012-06-18 Impact factor: 3.240
Authors: David R Bonsall; Michelle Kokkinou; Mattia Veronese; Christopher Coello; Lisa A Wells; Oliver D Howes Journal: J Neurochem Date: 2017-10-26 Impact factor: 5.372